Abstract Details

Title Infections leading to hospitalization or sepsis preceding clinically diagnosed a-synucleinopathies: a case-control study in Olmsted County, MN (1991-2010).

Topic Movement Disorders

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-049

Objective

We investigated the association between infections complicated by hospitalizations or sepsis and the development of α-synucleinopathies of any type.

Background Few studies have evaluated α-synucleinopathies within a population and studied the exposures, such as infections, associated with each type.

Design/Methods We used the medical records-linkage system of the Rochester Epidemiology Project to identify all cases of α-synucleinopathies in Olmsted County from 1991 to 2010. Each case was matched by age (+/- 1 year) of symptom onset and sex to a general population control. We reviewed the complete medical records of cases and controls to detect infections requiring hospitalization prior to the motor symptom onset of α-synucleinopathies of any type. For each infection, we also reviewed for sepsis development. We used conditional logistic regression to calculate the odds ratio of all α-synucleinopathies, as well as by type.

Results A history of at least one infection leading to hospitalization was associated with 0.76 fold decreased odds of an α-synucleinopathy diagnosis of any type in univariate analyses (95% confidence interval: 0.58-0.99, p=0.04). When analyzing by type, no specific α-synucleinopathies were significantly associated with infections leading to hospitalization. Although sepsis was less frequent among the cases compared to the matched controls (12 cases (2.6%) vs. 16 cases (3.4%)), sepsis was not significantly associated with α-synucleinopathies of any type (OR: 0.75, 95% CI 0.35-1.59, p=0.50).

Conclusions Infections leading to hospitalization was associated with decreased risk of developing any α-synucleinopathy. Future analysis will determine if certain types of infections, antibiotics, or even length of hospital stay contribute to and further explain these findings.

Authors/Disclosures
Shemonti Hasan, MD PRESENTER	Dr. Hasan has nothing to disclose.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine)	Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
J. E. Ahlskog, MD, PhD (Mayo Clinic)	Dr. Ahlskog has received publishing royalties from a publication relating to health care.
James H. Bower, MD, MSc, FAAN (Mayo Clinic)	The institution of Dr. Bower has received research support from Abbvie.
Pierpaolo Turcano, MD (Rush University Medical Center)	Dr. Turcano has nothing to disclose.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.

��ɫ��

��ɫ��